The development of orally active peptides: Prioritizing drug-likeness or bioactivity?
Acta Pharmaceutica Sinica B · 2026-10
DOI: 10.1016/j.apsb.2026.10.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-10. Verfasst von Sanhu Gou und 7 weiteren Autor:innen. Die Arbeit nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- CAMS Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
Zitieren
APA
Gou, S., Ba, Z., Ren, B., Liu, H., Zhang, Y., Zhong, C., Dong, Y., & Ni, J. (2026). The development of orally active peptides: Prioritizing drug-likeness or bioactivity?. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.10.032
Vancouver
Gou S, Ba Z, Ren B, Liu H, Zhang Y, Zhong C, et al. The development of orally active peptides: Prioritizing drug-likeness or bioactivity?. Acta Pharmaceutica Sinica B. 2026. doi:10.1016/j.apsb.2026.10.032
BibTeX
@article{Gou2026,
author = {Gou, Sanhu and Ba, Zufang and Ren, Bingqian and Liu, Hui and Zhang, Yun and Zhong, Chao and Dong, Yongxi and Ni, Jingman},
title = {The development of orally active peptides: Prioritizing drug-likeness or bioactivity?},
journal = {Acta Pharmaceutica Sinica B},
year = {2026},
doi = {10.1016/j.apsb.2026.10.032}
}
EUVIMED